Alectinib

(Alecensa®)

Alectinib

Drug updated on 11/16/2023

Dosage FormCapsule (oral; 150 mg)
Drug ClassKinase inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.

Product Monograph / Prescribing Information

Document TitleYearSource
Alecensa (alectinib) Prescribing Information.2021Genentech USA, Inc., South San Francisco, CA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Efficacy and safety of anaplastic lymphoma kinase inhibitors for non–small cell lung cancer: A systematic review and network meta-analysis.2023Thoracic Cancer
Comparative Efficacy of ALK Inhibitors for Treatment-Naïve ALK-Positive Advanced Non-Small Cell Lung Cancer with Central Nervous System Metastasis: A Network Meta-Analysis2023Cancer
Alectinib for treating patients with metastatic ALK-positive NSCLC: systematic review and network metanalysis2023Lung cancer management
Comparative safety of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced anaplastic lymphoma kinase-mutated non-small cell lung cancer: Systematic review and network meta-analysis2023Lung Cancer
A Bayesian network meta-analysis of ALK inhibitor treatments in patients with ALK-positive non-small cell lung cancer2023Cancer medicine
Safety and efficacy of alectinib versus crizotinib in alk-positive non-small cell lung cancer: An update meta-analysis2023Pakistan journal of pharmaceutical sciences
A Systematic Review of the Cost-Effectiveness Analyses of Anaplastic Lymphoma Kinase (ALK) Inhibitors in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)2023Pharmacoeconomics
Efficacy and safety of anaplastic lymphoma kinase inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis2023Thoracic cancer
Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer.2022Cochrane Database of Systematic Reviews
A systematic review of companion diagnostic tests by immunohistochemistry for the screening of alectinib-treated patients in ALK-positive non-small cell lung cancer. 2022Diagnostics
Toxicity profile of anaplastic lymphoma kinase tyrosine kinase inhibitors for patients with non small cell lung cancer: a systematic review and meta analysis. 2022Investigational New Drugs
First-line treatments for patients with advanced ALK gene rearrangements in NSCLC: a systematic review and network meta-analysis.2022Journal of International Medical Research
Indirect comparisons of brigatinib and alectinib for front-line ALK-positive non-small-cell lung cancer2022Future oncology
Front-line treatment for advanced non-small-cell lung cancer and ALK fusion: a network meta-analysis2022Journal of clinical medicine
Crizotinib versus Alectinib for the Treatment of ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis2022Chemotherapy
Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase-positive non-small cell lung cancer using data from ALEX and final results from ALTA-1L2022Current medical research and opinion
First-line anaplastic lymphoma kinase (ALK) inhibitors for ALK-positive lung cancer in Asian populations: systematic review and network meta-analysis. 2021Journal of Clinical Medicine
Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials. 2021BMC Cancer
Crizotinib versus alectinib for the treatment of ALK-positive non-small cell lung cancer: a systematic review and meta-analysis.2021Chemotherapy
Systematic review and network meta-analysis of anaplastic lymphoma kinase (ALK) inhibitors for treatment-naïve ALK-positive lung cancer. 2021Cancers
Comparison of lorlatinib, alectinib and brigatinib in ALK inhibitor–naive/untreated ALK-positive advanced non-small-cell lung cancer: a systematic review and network meta-analysis. 2021Journal of Chemotherapy
Comparative efficacy and safety of lorlatinib and alectinib for ALK-rearrangement positive advanced non-small cell lung cancer in Asian and non-Asian patients: a systematic review and network meta-analysis. 2021Cancers
Comparison of clinical efficacy of alectinib versus crizotinib in ALK-positive non-small cell lung cancer: a meta-analysis. 2021Frontiers in Oncology
ALK inhibitor-induced bradycardia: A systematic-review and meta-analysis2021Lung Cancer
Front-line treatment for advanced non-small-cell lung cancer and ALK fusion: a network meta-analysis2021Pharmacological research
A Bayesian network meta-analysis regarding the comparative efficacy of therapeutics for ALK-positive, brain metastatic non-small cell lung cancer2021Pharmacological research
Comparison of Clinical Efficacy of Alectinib Versus Crizotinib in ALK-Positive Non-Small Cell Lung Cancer: A Meta-Analysis2021Frontiers in oncology
Efficacy and Safety of First-Line Treatment Strategies for Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis2021Frontiers in oncology
Comparative Efficacy of Systemic Agents for Brain Metastases From Non-Small-Cell Lung Cancer With an EGFR Mutation/ALK Rearrangement: A Systematic Review and Network Meta-Analysis2021Frontiers in oncology
Brigatinib and alectinib for ALK rearrangement-positive advanced non-small cell lung cancer with or without central nervous system metastasis: a systematic review and network meta-analysis.2020Cancers
ALK inhibitors for non-small cell lung cancer: a systematic review and network meta-analysis.2020PLoS One
Effect of alectinib versus crizotinib on progression-free survival, central nervous system efficacy and adverse events in ALK-positive non-small cell lung cancer: a systematic review and meta-analysis.2020Annals of Palliative Medicine
Cost Effectiveness of Ceritinib and Alectinib Versus Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-small-cell Lung Cancer2020Clinical drug investigation
Comparative Efficacy of Targeted Therapies in Patients with Non-Small Cell Lung Cancer: A Network Meta-Analysis of Clinical Trials2020Journal of clinical medicine
Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer2020Lung cancer
Efficacy of Crizotinib, Ceritinib, and Alectinib in ALK-Positive Non-Small Cell Lung Cancer Treatment: A Meta-Analysis of Clinical Trials 2020Cancers
Effect of alectinib versus crizotinib on progression-free survival, central nervous system efficacy and adverse events in ALK-positive non-small cell lung cancer: a systematic review and meta-analysis2020Annals of palliative medicine
Meta-analysis of overall incidence and risk of ALK inhibitors-induced liver toxicities in advanced non-small-cell lung cancer2019Medicine (Baltimore)
ALK Inhibitors in the Treatment of ALK Positive NSCLC2019Frontiers in Oncology
Safety issues with the ALK inhibitors in the treatment of NSCLC: A systematic review2019Critical reviews in oncology/hematology
The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis2019Cancer management and research
The incidence of ALK inhibitor-related pneumonitis in advanced non-small-cell lung cancer patients: A systematic review and meta-analysis2019Lung cancer
Anaplastic lymphoma kinase inhibitors in non-small cell lung cancer patients with brain metastases: a meta-analysis2019Journal of thoracic disease
The efficacy and safety of alectinib in the treatment of ALK+ NSCLC: a systematic review and meta-analysis.2018OncoTargets and Therapy
Final clinical guidance report: alectinib (Alecensaro).2018CADTH
Alectinib (Alecensa©) as monotherapy for the first line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC)2018EUNETHTA
ALK inhibitors in ALK-rearranged non-small cell lung cancer with and without brain metastases: systematic review and network meta-analysis2018BMJ Open
Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer2018Oncotarget
The efficacy and safety of alectinib in the treatment of ALK+ NSCLC: a systematic review and meta-analysis2018OncoTargets and therapy
The efficacy and safety of ALK inhibitors in the treatment of ALK-positive non-small cell lung cancer: A network meta-analysis2018Cancer medicine

Clinical Practice Guidelines